Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A rationale for an individualized haemoglobin target.

Norman Muirhead1

  • 1University of Western Ontario, London, Ontario, Canada.

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|July 2, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using dalteparin in quotidian and nocturnal hemodialysis patients: A prospective study.

Hemodialysis international. International Symposium on Home Hemodialysis·2019
Same author

An Adjustable Dalteparin Sodium Dose Regimen for the Prevention of Clotting in the Extracorporeal Circuit in Hemodialysis: A Clinical Trial of Safety and Efficacy (the PARROT Study).

Canadian journal of kidney health and disease·2018
Same author

Transfusion Management of Incident Dialysis Patients in Canada: A Prospective Observational Study.

Canadian journal of kidney health and disease·2018
Same author

Effect of Coaching to Increase Water Intake on Kidney Function Decline in Adults With Chronic Kidney Disease: The CKD WIT Randomized Clinical Trial.

JAMA·2018
Same author

Randomized open-label crossover assessment of Prograf vs Advagraf on immunosuppressant pharmacokinetics and pharmacodynamics in simultaneous pancreas-kidney patients.

Clinical transplantation·2017
Same author

Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events.

Kidney international·2016

Optimal haemoglobin (Hb) targets for treating renal anaemia with recombinant human erythropoietin (rh-EPO) remain debated. Individualized Hb targets are recommended, as higher levels may harm cardiac patients but benefit healthier dialysis patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Hematology

Background:

  • Recombinant human erythropoietin (rh-EPO) is widely used for renal anaemia, but optimal haemoglobin (Hb) targets are debated.
  • Current guidelines suggest partial anaemia correction, based on older trials.
  • Recent studies present conflicting results regarding the benefits and risks of normalizing Hb levels.

Purpose of the Study:

  • To evaluate the impact of different haemoglobin (Hb) targets in patients with renal anaemia treated with rh-EPO.
  • To determine if normalizing Hb levels is beneficial or detrimental based on patient cardiac status.

Main Methods:

  • Review of recent randomized clinical trials comparing different Hb target levels in dialysis patients.
  • Analysis of adverse events, quality of life, exercise capacity, and cardiac outcomes.

Related Experiment Videos

Main Results:

  • A US study in patients with pre-existing cardiac disease showed increased cardiac mortality and haemodialysis access failure with higher Hb levels.
  • Three studies in healthier dialysis patients (Australia, Spain, Canada) demonstrated improved quality of life, exercise capacity, and slower left ventricular dilatation with normalized Hb levels.
  • No unacceptable increase in adverse effects was observed in healthier patient groups.

Conclusions:

  • Higher Hb levels may be detrimental in patients with pre-existing cardiac conditions.
  • Healthier dialysis patients appear to benefit from normalized Hb levels.
  • Individualized Hb targets, rather than a single universal target, are recommended for patient-centred care.